nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—EGFR—type 2 diabetes mellitus	0.14	0.447	CbGaD
Erlotinib—CYP1A2—type 2 diabetes mellitus	0.0774	0.247	CbGaD
Erlotinib—CYP3A4—type 2 diabetes mellitus	0.0513	0.163	CbGaD
Erlotinib—ALB—type 2 diabetes mellitus	0.0447	0.143	CbGaD
Erlotinib—SLCO2B1—Tolbutamide—type 2 diabetes mellitus	0.044	0.105	CbGbCtD
Erlotinib—SLCO2B1—Glyburide—type 2 diabetes mellitus	0.0253	0.0603	CbGbCtD
Erlotinib—ORM1—Nateglinide—type 2 diabetes mellitus	0.0252	0.0601	CbGbCtD
Erlotinib—UGT1A1—Losartan—type 2 diabetes mellitus	0.0173	0.0412	CbGbCtD
Erlotinib—ALB—Gliclazide—type 2 diabetes mellitus	0.0164	0.0392	CbGbCtD
Erlotinib—ALB—Repaglinide—type 2 diabetes mellitus	0.0155	0.0369	CbGbCtD
Erlotinib—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0149	0.0357	CbGbCtD
Erlotinib—ALB—Rosiglitazone—type 2 diabetes mellitus	0.0129	0.0308	CbGbCtD
Erlotinib—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0119	0.0285	CbGbCtD
Erlotinib—ALB—Valsartan—type 2 diabetes mellitus	0.0114	0.0272	CbGbCtD
Erlotinib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0113	0.0271	CbGbCtD
Erlotinib—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.0108	0.0258	CbGbCtD
Erlotinib—ALB—Nateglinide—type 2 diabetes mellitus	0.0106	0.0253	CbGbCtD
Erlotinib—ABCG2—Glyburide—type 2 diabetes mellitus	0.0104	0.0248	CbGbCtD
Erlotinib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0101	0.0241	CbGbCtD
Erlotinib—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.00997	0.0238	CbGbCtD
Erlotinib—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.00963	0.023	CbGbCtD
Erlotinib—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.00851	0.0203	CbGbCtD
Erlotinib—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.00785	0.0187	CbGbCtD
Erlotinib—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.00772	0.0184	CbGbCtD
Erlotinib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00731	0.0174	CbGbCtD
Erlotinib—ALB—Glyburide—type 2 diabetes mellitus	0.00715	0.0171	CbGbCtD
Erlotinib—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00689	0.0164	CbGbCtD
Erlotinib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0068	0.0162	CbGbCtD
Erlotinib—ALB—Losartan—type 2 diabetes mellitus	0.00654	0.0156	CbGbCtD
Erlotinib—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00636	0.0152	CbGbCtD
Erlotinib—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00607	0.0145	CbGbCtD
Erlotinib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00606	0.0145	CbGbCtD
Erlotinib—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00574	0.0137	CbGbCtD
Erlotinib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00554	0.0132	CbGbCtD
Erlotinib—CYP3A5—Losartan—type 2 diabetes mellitus	0.00526	0.0126	CbGbCtD
Erlotinib—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00522	0.0125	CbGbCtD
Erlotinib—CYP2C8—Losartan—type 2 diabetes mellitus	0.00506	0.0121	CbGbCtD
Erlotinib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00502	0.012	CbGbCtD
Erlotinib—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.005	0.0119	CbGbCtD
Erlotinib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00484	0.0116	CbGbCtD
Erlotinib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00438	0.0105	CbGbCtD
Erlotinib—CYP1A2—Losartan—type 2 diabetes mellitus	0.00391	0.00934	CbGbCtD
Erlotinib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00374	0.00893	CbGbCtD
Erlotinib—ABCB1—Losartan—type 2 diabetes mellitus	0.00342	0.00817	CbGbCtD
Erlotinib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00332	0.00792	CbGbCtD
Erlotinib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00318	0.0076	CbGbCtD
Erlotinib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00318	0.0076	CbGbCtD
Erlotinib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00301	0.00718	CbGbCtD
Erlotinib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00224	0.00535	CbGbCtD
Erlotinib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00205	0.0049	CbGbCtD
Erlotinib—PIP4K2C—islet of Langerhans—type 2 diabetes mellitus	0.000906	0.0281	CbGeAlD
Erlotinib—JAK3—adipose tissue—type 2 diabetes mellitus	0.000811	0.0251	CbGeAlD
Erlotinib—PIP4K2C—retina—type 2 diabetes mellitus	0.000774	0.024	CbGeAlD
Erlotinib—SLK—islet of Langerhans—type 2 diabetes mellitus	0.000771	0.0239	CbGeAlD
Erlotinib—ULK3—retina—type 2 diabetes mellitus	0.000739	0.0229	CbGeAlD
Erlotinib—PIP4K2C—nephron tubule—type 2 diabetes mellitus	0.000729	0.0226	CbGeAlD
Erlotinib—FLT3—cardiovascular system—type 2 diabetes mellitus	0.000725	0.0225	CbGeAlD
Erlotinib—NR1I2—liver—type 2 diabetes mellitus	0.000711	0.022	CbGeAlD
Erlotinib—MKNK1—retina—type 2 diabetes mellitus	0.000696	0.0216	CbGeAlD
Erlotinib—Vandetanib—SRC—type 2 diabetes mellitus	0.000686	0.25	CrCbGaD
Erlotinib—PIP4K2C—pancreas—type 2 diabetes mellitus	0.000637	0.0197	CbGeAlD
Erlotinib—PIP4K2C—cortex of kidney—type 2 diabetes mellitus	0.000624	0.0194	CbGeAlD
Erlotinib—SLK—nephron tubule—type 2 diabetes mellitus	0.000621	0.0192	CbGeAlD
Erlotinib—ABL2—adipose tissue—type 2 diabetes mellitus	0.00061	0.0189	CbGeAlD
Erlotinib—ULK3—cortex of kidney—type 2 diabetes mellitus	0.000596	0.0185	CbGeAlD
Erlotinib—EGFR—adipose tissue—type 2 diabetes mellitus	0.000596	0.0185	CbGeAlD
Erlotinib—MKNK1—cardiovascular system—type 2 diabetes mellitus	0.000589	0.0183	CbGeAlD
Erlotinib—PIP4K2C—adipose tissue—type 2 diabetes mellitus	0.000578	0.0179	CbGeAlD
Erlotinib—MKNK1—cortex of kidney—type 2 diabetes mellitus	0.000561	0.0174	CbGeAlD
Erlotinib—ULK3—adipose tissue—type 2 diabetes mellitus	0.000551	0.0171	CbGeAlD
Erlotinib—Vandetanib—VEGFA—type 2 diabetes mellitus	0.000547	0.199	CrCbGaD
Erlotinib—SLK—pancreas—type 2 diabetes mellitus	0.000542	0.0168	CbGeAlD
Erlotinib—SLK—cortex of kidney—type 2 diabetes mellitus	0.000531	0.0165	CbGeAlD
Erlotinib—TNK1—liver—type 2 diabetes mellitus	0.000522	0.0162	CbGeAlD
Erlotinib—MKNK1—adipose tissue—type 2 diabetes mellitus	0.000519	0.0161	CbGeAlD
Erlotinib—SLK—adipose tissue—type 2 diabetes mellitus	0.000492	0.0152	CbGeAlD
Erlotinib—STK10—cardiovascular system—type 2 diabetes mellitus	0.000485	0.015	CbGeAlD
Erlotinib—STK10—kidney—type 2 diabetes mellitus	0.000474	0.0147	CbGeAlD
Erlotinib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.000462	0.0143	CbGeAlD
Erlotinib—Vandetanib—EGFR—type 2 diabetes mellitus	0.000461	0.168	CrCbGaD
Erlotinib—FLT3—liver—type 2 diabetes mellitus	0.000448	0.0139	CbGeAlD
Erlotinib—UGT1A1—kidney—type 2 diabetes mellitus	0.000448	0.0139	CbGeAlD
Erlotinib—Gefitinib—EGFR—type 2 diabetes mellitus	0.000438	0.16	CrCbGaD
Erlotinib—MAP2K5—cardiovascular system—type 2 diabetes mellitus	0.000433	0.0134	CbGeAlD
Erlotinib—ABL2—liver—type 2 diabetes mellitus	0.000428	0.0133	CbGeAlD
Erlotinib—STK10—adipose tissue—type 2 diabetes mellitus	0.000427	0.0133	CbGeAlD
Erlotinib—EGFR—liver—type 2 diabetes mellitus	0.000418	0.013	CbGeAlD
Erlotinib—MAP2K5—cortex of kidney—type 2 diabetes mellitus	0.000412	0.0128	CbGeAlD
Erlotinib—PIP4K2C—liver—type 2 diabetes mellitus	0.000405	0.0126	CbGeAlD
Erlotinib—ABL1—retina—type 2 diabetes mellitus	0.000395	0.0122	CbGeAlD
Erlotinib—ULK3—liver—type 2 diabetes mellitus	0.000387	0.012	CbGeAlD
Erlotinib—MAP2K5—adipose tissue—type 2 diabetes mellitus	0.000382	0.0118	CbGeAlD
Erlotinib—ABL1—nephron tubule—type 2 diabetes mellitus	0.000372	0.0115	CbGeAlD
Erlotinib—MKNK1—liver—type 2 diabetes mellitus	0.000364	0.0113	CbGeAlD
Erlotinib—SLK—liver—type 2 diabetes mellitus	0.000345	0.0107	CbGeAlD
Erlotinib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000334	0.0104	CbGeAlD
Erlotinib—SLCO2B1—kidney—type 2 diabetes mellitus	0.00033	0.0102	CbGeAlD
Erlotinib—ABL1—kidney—type 2 diabetes mellitus	0.000327	0.0101	CbGeAlD
Erlotinib—ABL1—pancreas—type 2 diabetes mellitus	0.000325	0.0101	CbGeAlD
Erlotinib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.000318	0.00987	CbGeAlD
Erlotinib—CYP1B1—nephron tubule—type 2 diabetes mellitus	0.000315	0.00976	CbGeAlD
Erlotinib—STK10—liver—type 2 diabetes mellitus	0.0003	0.00929	CbGeAlD
Erlotinib—SLCO2B1—adipose tissue—type 2 diabetes mellitus	0.000297	0.00921	CbGeAlD
Erlotinib—ABL1—adipose tissue—type 2 diabetes mellitus	0.000294	0.00913	CbGeAlD
Erlotinib—UGT1A1—liver—type 2 diabetes mellitus	0.000283	0.00878	CbGeAlD
Erlotinib—CYP1B1—cardiovascular system—type 2 diabetes mellitus	0.000283	0.00877	CbGeAlD
Erlotinib—CYP1B1—kidney—type 2 diabetes mellitus	0.000277	0.00858	CbGeAlD
Erlotinib—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.00027	0.00838	CbGeAlD
Erlotinib—CYP1B1—cortex of kidney—type 2 diabetes mellitus	0.000269	0.00836	CbGeAlD
Erlotinib—MAP2K5—liver—type 2 diabetes mellitus	0.000268	0.0083	CbGeAlD
Erlotinib—CYP1B1—adipose tissue—type 2 diabetes mellitus	0.000249	0.00773	CbGeAlD
Erlotinib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000234	0.00727	CbGeAlD
Erlotinib—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000218	0.00675	CbGeAlD
Erlotinib—ORM1—liver—type 2 diabetes mellitus	0.000217	0.00674	CbGeAlD
Erlotinib—CYP2C8—kidney—type 2 diabetes mellitus	0.000212	0.00657	CbGeAlD
Erlotinib—SLCO2B1—liver—type 2 diabetes mellitus	0.000208	0.00646	CbGeAlD
Erlotinib—ABL1—liver—type 2 diabetes mellitus	0.000207	0.0064	CbGeAlD
Erlotinib—CYP1A1—kidney—type 2 diabetes mellitus	0.000196	0.00607	CbGeAlD
Erlotinib—CYP3A5—kidney—type 2 diabetes mellitus	0.000191	0.00593	CbGeAlD
Erlotinib—ALB—liver—type 2 diabetes mellitus	0.000191	0.00591	CbGeAlD
Erlotinib—CYP3A5—pancreas—type 2 diabetes mellitus	0.00019	0.00589	CbGeAlD
Erlotinib—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000186	0.00578	CbGeAlD
Erlotinib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000186	0.00576	CbGeAlD
Erlotinib—CYP1A1—adipose tissue—type 2 diabetes mellitus	0.000176	0.00547	CbGeAlD
Erlotinib—CYP1B1—liver—type 2 diabetes mellitus	0.000175	0.00542	CbGeAlD
Erlotinib—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000172	0.00534	CbGeAlD
Erlotinib—Vandetanib—CYP3A4—type 2 diabetes mellitus	0.000168	0.0613	CrCbGaD
Erlotinib—Gefitinib—CYP3A4—type 2 diabetes mellitus	0.00016	0.0583	CrCbGaD
Erlotinib—Vandetanib—ALB—type 2 diabetes mellitus	0.000147	0.0535	CrCbGaD
Erlotinib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000144	0.00445	CbGeAlD
Erlotinib—CYP3A4—kidney—type 2 diabetes mellitus	0.000144	0.00445	CbGeAlD
Erlotinib—CYP2D6—kidney—type 2 diabetes mellitus	0.000141	0.00438	CbGeAlD
Erlotinib—Gefitinib—ALB—type 2 diabetes mellitus	0.00014	0.0508	CrCbGaD
Erlotinib—CYP2C8—liver—type 2 diabetes mellitus	0.000134	0.00415	CbGeAlD
Erlotinib—ABCG2—liver—type 2 diabetes mellitus	0.00013	0.00404	CbGeAlD
Erlotinib—CYP1A2—liver—type 2 diabetes mellitus	0.000125	0.00389	CbGeAlD
Erlotinib—CYP1A1—liver—type 2 diabetes mellitus	0.000124	0.00383	CbGeAlD
Erlotinib—ABCB1—retina—type 2 diabetes mellitus	0.000123	0.00381	CbGeAlD
Erlotinib—CYP3A5—liver—type 2 diabetes mellitus	0.000121	0.00375	CbGeAlD
Erlotinib—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000116	0.00358	CbGeAlD
Erlotinib—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000104	0.00322	CbGeAlD
Erlotinib—ABCB1—kidney—type 2 diabetes mellitus	0.000102	0.00315	CbGeAlD
Erlotinib—ABCB1—pancreas—type 2 diabetes mellitus	0.000101	0.00313	CbGeAlD
Erlotinib—ABCB1—cortex of kidney—type 2 diabetes mellitus	9.89e-05	0.00307	CbGeAlD
Erlotinib—Vomiting—Glipizide—type 2 diabetes mellitus	9.38e-05	0.000698	CcSEcCtD
Erlotinib—Syncope—Metformin—type 2 diabetes mellitus	9.37e-05	0.000698	CcSEcCtD
Erlotinib—Oedema—Valsartan—type 2 diabetes mellitus	9.36e-05	0.000697	CcSEcCtD
Erlotinib—Dizziness—Pioglitazone—type 2 diabetes mellitus	9.34e-05	0.000696	CcSEcCtD
Erlotinib—Infection—Valsartan—type 2 diabetes mellitus	9.3e-05	0.000693	CcSEcCtD
Erlotinib—Rash—Glipizide—type 2 diabetes mellitus	9.3e-05	0.000693	CcSEcCtD
Erlotinib—Dermatitis—Glipizide—type 2 diabetes mellitus	9.29e-05	0.000692	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	9.28e-05	0.000692	CcSEcCtD
Erlotinib—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	9.28e-05	0.000691	CcSEcCtD
Erlotinib—Erythema—Losartan—type 2 diabetes mellitus	9.28e-05	0.000691	CcSEcCtD
Erlotinib—Oedema—Orlistat—type 2 diabetes mellitus	9.25e-05	0.000689	CcSEcCtD
Erlotinib—Headache—Glipizide—type 2 diabetes mellitus	9.24e-05	0.000688	CcSEcCtD
Erlotinib—Insomnia—Gliclazide—type 2 diabetes mellitus	9.22e-05	0.000687	CcSEcCtD
Erlotinib—Shock—Valsartan—type 2 diabetes mellitus	9.21e-05	0.000686	CcSEcCtD
Erlotinib—Infection—Orlistat—type 2 diabetes mellitus	9.19e-05	0.000685	CcSEcCtD
Erlotinib—Loss of consciousness—Metformin—type 2 diabetes mellitus	9.18e-05	0.000684	CcSEcCtD
Erlotinib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	9.18e-05	0.000684	CcSEcCtD
Erlotinib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	9.17e-05	0.000683	CcSEcCtD
Erlotinib—ABCB1—adipose tissue—type 2 diabetes mellitus	9.16e-05	0.00284	CbGeAlD
Erlotinib—Flatulence—Losartan—type 2 diabetes mellitus	9.14e-05	0.000681	CcSEcCtD
Erlotinib—Hepatitis—Ramipril—type 2 diabetes mellitus	9.14e-05	0.000681	CcSEcCtD
Erlotinib—Dizziness—Glimepiride—type 2 diabetes mellitus	9.1e-05	0.000678	CcSEcCtD
Erlotinib—Skin disorder—Valsartan—type 2 diabetes mellitus	9.09e-05	0.000677	CcSEcCtD
Erlotinib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	9.09e-05	0.000677	CcSEcCtD
Erlotinib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	9.07e-05	0.000676	CcSEcCtD
Erlotinib—CYP3A4—liver—type 2 diabetes mellitus	9.07e-05	0.00281	CbGeAlD
Erlotinib—Dizziness—Sitagliptin—type 2 diabetes mellitus	9.07e-05	0.000676	CcSEcCtD
Erlotinib—Skin disorder—Orlistat—type 2 diabetes mellitus	8.99e-05	0.000669	CcSEcCtD
Erlotinib—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	8.98e-05	0.000669	CcSEcCtD
Erlotinib—Back pain—Losartan—type 2 diabetes mellitus	8.97e-05	0.000669	CcSEcCtD
Erlotinib—Abdominal pain—Glyburide—type 2 diabetes mellitus	8.97e-05	0.000668	CcSEcCtD
Erlotinib—Dyspepsia—Gliclazide—type 2 diabetes mellitus	8.97e-05	0.000668	CcSEcCtD
Erlotinib—CYP2D6—liver—type 2 diabetes mellitus	8.93e-05	0.00277	CbGeAlD
Erlotinib—Anorexia—Valsartan—type 2 diabetes mellitus	8.92e-05	0.000665	CcSEcCtD
Erlotinib—Asthenia—Bromocriptine—type 2 diabetes mellitus	8.91e-05	0.000664	CcSEcCtD
Erlotinib—Myalgia—Metformin—type 2 diabetes mellitus	8.89e-05	0.000663	CcSEcCtD
Erlotinib—Chest pain—Metformin—type 2 diabetes mellitus	8.89e-05	0.000663	CcSEcCtD
Erlotinib—Headache—Pioglitazone—type 2 diabetes mellitus	8.85e-05	0.000659	CcSEcCtD
Erlotinib—Syncope—Irbesartan—type 2 diabetes mellitus	8.84e-05	0.000659	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	8.83e-05	0.000658	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	8.8e-05	0.000655	CcSEcCtD
Erlotinib—Fatigue—Gliclazide—type 2 diabetes mellitus	8.79e-05	0.000654	CcSEcCtD
Erlotinib—Nausea—Glipizide—type 2 diabetes mellitus	8.76e-05	0.000652	CcSEcCtD
Erlotinib—Vomiting—Glimepiride—type 2 diabetes mellitus	8.75e-05	0.000652	CcSEcCtD
Erlotinib—Vomiting—Sitagliptin—type 2 diabetes mellitus	8.72e-05	0.00065	CcSEcCtD
Erlotinib—Pain—Gliclazide—type 2 diabetes mellitus	8.71e-05	0.000649	CcSEcCtD
Erlotinib—Constipation—Gliclazide—type 2 diabetes mellitus	8.71e-05	0.000649	CcSEcCtD
Erlotinib—Rash—Glimepiride—type 2 diabetes mellitus	8.68e-05	0.000646	CcSEcCtD
Erlotinib—Dermatitis—Glimepiride—type 2 diabetes mellitus	8.67e-05	0.000646	CcSEcCtD
Erlotinib—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	8.67e-05	0.000645	CcSEcCtD
Erlotinib—Rash—Sitagliptin—type 2 diabetes mellitus	8.65e-05	0.000644	CcSEcCtD
Erlotinib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	8.64e-05	0.000644	CcSEcCtD
Erlotinib—Erythema multiforme—Ramipril—type 2 diabetes mellitus	8.64e-05	0.000644	CcSEcCtD
Erlotinib—Headache—Glimepiride—type 2 diabetes mellitus	8.62e-05	0.000642	CcSEcCtD
Erlotinib—Cough—Irbesartan—type 2 diabetes mellitus	8.6e-05	0.000641	CcSEcCtD
Erlotinib—Headache—Sitagliptin—type 2 diabetes mellitus	8.59e-05	0.00064	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	8.53e-05	0.000635	CcSEcCtD
Erlotinib—Oedema—Metformin—type 2 diabetes mellitus	8.53e-05	0.000635	CcSEcCtD
Erlotinib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	8.49e-05	0.000633	CcSEcCtD
Erlotinib—Infection—Metformin—type 2 diabetes mellitus	8.47e-05	0.000631	CcSEcCtD
Erlotinib—Insomnia—Valsartan—type 2 diabetes mellitus	8.47e-05	0.000631	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	8.43e-05	0.000628	CcSEcCtD
Erlotinib—Myalgia—Irbesartan—type 2 diabetes mellitus	8.39e-05	0.000625	CcSEcCtD
Erlotinib—Chest pain—Irbesartan—type 2 diabetes mellitus	8.39e-05	0.000625	CcSEcCtD
Erlotinib—Arthralgia—Irbesartan—type 2 diabetes mellitus	8.39e-05	0.000625	CcSEcCtD
Erlotinib—Shock—Metformin—type 2 diabetes mellitus	8.39e-05	0.000625	CcSEcCtD
Erlotinib—Insomnia—Orlistat—type 2 diabetes mellitus	8.37e-05	0.000623	CcSEcCtD
Erlotinib—Anxiety—Irbesartan—type 2 diabetes mellitus	8.36e-05	0.000623	CcSEcCtD
Erlotinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	8.36e-05	0.000623	CcSEcCtD
Erlotinib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	8.35e-05	0.000622	CcSEcCtD
Erlotinib—Dyspnoea—Valsartan—type 2 diabetes mellitus	8.35e-05	0.000622	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	8.34e-05	0.000621	CcSEcCtD
Erlotinib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	8.33e-05	0.000621	CcSEcCtD
Erlotinib—Syncope—Losartan—type 2 diabetes mellitus	8.32e-05	0.00062	CcSEcCtD
Erlotinib—Skin disorder—Metformin—type 2 diabetes mellitus	8.28e-05	0.000617	CcSEcCtD
Erlotinib—Dyspepsia—Valsartan—type 2 diabetes mellitus	8.24e-05	0.000614	CcSEcCtD
Erlotinib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	8.24e-05	0.000614	CcSEcCtD
Erlotinib—Dizziness—Bromocriptine—type 2 diabetes mellitus	8.21e-05	0.000612	CcSEcCtD
Erlotinib—Nausea—Glimepiride—type 2 diabetes mellitus	8.17e-05	0.000609	CcSEcCtD
Erlotinib—Arrhythmia—Ramipril—type 2 diabetes mellitus	8.16e-05	0.000608	CcSEcCtD
Erlotinib—Loss of consciousness—Losartan—type 2 diabetes mellitus	8.15e-05	0.000607	CcSEcCtD
Erlotinib—Nausea—Sitagliptin—type 2 diabetes mellitus	8.15e-05	0.000607	CcSEcCtD
Erlotinib—Dyspepsia—Orlistat—type 2 diabetes mellitus	8.14e-05	0.000607	CcSEcCtD
Erlotinib—Asthenia—Glyburide—type 2 diabetes mellitus	8.14e-05	0.000607	CcSEcCtD
Erlotinib—Decreased appetite—Valsartan—type 2 diabetes mellitus	8.14e-05	0.000606	CcSEcCtD
Erlotinib—Anorexia—Metformin—type 2 diabetes mellitus	8.13e-05	0.000605	CcSEcCtD
Erlotinib—Cough—Losartan—type 2 diabetes mellitus	8.1e-05	0.000603	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	8.08e-05	0.000602	CcSEcCtD
Erlotinib—Alopecia—Ramipril—type 2 diabetes mellitus	8.08e-05	0.000602	CcSEcCtD
Erlotinib—Fatigue—Valsartan—type 2 diabetes mellitus	8.07e-05	0.000601	CcSEcCtD
Erlotinib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	8.06e-05	0.0006	CcSEcCtD
Erlotinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	8.06e-05	0.0006	CcSEcCtD
Erlotinib—Oedema—Irbesartan—type 2 diabetes mellitus	8.05e-05	0.000599	CcSEcCtD
Erlotinib—Decreased appetite—Orlistat—type 2 diabetes mellitus	8.04e-05	0.000599	CcSEcCtD
Erlotinib—Pruritus—Glyburide—type 2 diabetes mellitus	8.03e-05	0.000598	CcSEcCtD
Erlotinib—Mental disorder—Ramipril—type 2 diabetes mellitus	8.01e-05	0.000596	CcSEcCtD
Erlotinib—Constipation—Valsartan—type 2 diabetes mellitus	8.01e-05	0.000596	CcSEcCtD
Erlotinib—Infection—Irbesartan—type 2 diabetes mellitus	7.99e-05	0.000595	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	7.99e-05	0.000595	CcSEcCtD
Erlotinib—Fatigue—Orlistat—type 2 diabetes mellitus	7.98e-05	0.000594	CcSEcCtD
Erlotinib—Erythema—Ramipril—type 2 diabetes mellitus	7.96e-05	0.000593	CcSEcCtD
Erlotinib—Malnutrition—Ramipril—type 2 diabetes mellitus	7.96e-05	0.000593	CcSEcCtD
Erlotinib—Shock—Irbesartan—type 2 diabetes mellitus	7.92e-05	0.00059	CcSEcCtD
Erlotinib—Pain—Orlistat—type 2 diabetes mellitus	7.91e-05	0.000589	CcSEcCtD
Erlotinib—Arthralgia—Losartan—type 2 diabetes mellitus	7.9e-05	0.000588	CcSEcCtD
Erlotinib—Chest pain—Losartan—type 2 diabetes mellitus	7.9e-05	0.000588	CcSEcCtD
Erlotinib—Myalgia—Losartan—type 2 diabetes mellitus	7.9e-05	0.000588	CcSEcCtD
Erlotinib—Vomiting—Bromocriptine—type 2 diabetes mellitus	7.89e-05	0.000588	CcSEcCtD
Erlotinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	7.89e-05	0.000588	CcSEcCtD
Erlotinib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	7.88e-05	0.000587	CcSEcCtD
Erlotinib—Anxiety—Losartan—type 2 diabetes mellitus	7.87e-05	0.000586	CcSEcCtD
Erlotinib—Rash—Bromocriptine—type 2 diabetes mellitus	7.83e-05	0.000583	CcSEcCtD
Erlotinib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	7.82e-05	0.000583	CcSEcCtD
Erlotinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	7.82e-05	0.000582	CcSEcCtD
Erlotinib—Headache—Bromocriptine—type 2 diabetes mellitus	7.78e-05	0.000579	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	7.77e-05	0.000579	CcSEcCtD
Erlotinib—Diarrhoea—Glyburide—type 2 diabetes mellitus	7.77e-05	0.000578	CcSEcCtD
Erlotinib—Anorexia—Irbesartan—type 2 diabetes mellitus	7.67e-05	0.000571	CcSEcCtD
Erlotinib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	7.66e-05	0.00057	CcSEcCtD
Erlotinib—Dyspnoea—Metformin—type 2 diabetes mellitus	7.6e-05	0.000566	CcSEcCtD
Erlotinib—Oedema—Losartan—type 2 diabetes mellitus	7.57e-05	0.000564	CcSEcCtD
Erlotinib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	7.57e-05	0.000564	CcSEcCtD
Erlotinib—Infection—Losartan—type 2 diabetes mellitus	7.52e-05	0.00056	CcSEcCtD
Erlotinib—Dyspepsia—Metformin—type 2 diabetes mellitus	7.51e-05	0.000559	CcSEcCtD
Erlotinib—Shock—Losartan—type 2 diabetes mellitus	7.45e-05	0.000555	CcSEcCtD
Erlotinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	7.43e-05	0.000553	CcSEcCtD
Erlotinib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	7.41e-05	0.000552	CcSEcCtD
Erlotinib—Decreased appetite—Metformin—type 2 diabetes mellitus	7.41e-05	0.000552	CcSEcCtD
Erlotinib—Abdominal pain—Valsartan—type 2 diabetes mellitus	7.4e-05	0.000551	CcSEcCtD
Erlotinib—Nausea—Bromocriptine—type 2 diabetes mellitus	7.37e-05	0.000549	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	7.36e-05	0.000548	CcSEcCtD
Erlotinib—Fatigue—Metformin—type 2 diabetes mellitus	7.35e-05	0.000548	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	7.33e-05	0.000546	CcSEcCtD
Erlotinib—Abdominal pain—Orlistat—type 2 diabetes mellitus	7.31e-05	0.000545	CcSEcCtD
Erlotinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	7.31e-05	0.000545	CcSEcCtD
Erlotinib—Asthenia—Gliclazide—type 2 diabetes mellitus	7.31e-05	0.000545	CcSEcCtD
Erlotinib—Constipation—Metformin—type 2 diabetes mellitus	7.29e-05	0.000543	CcSEcCtD
Erlotinib—Anorexia—Losartan—type 2 diabetes mellitus	7.22e-05	0.000538	CcSEcCtD
Erlotinib—Vomiting—Glyburide—type 2 diabetes mellitus	7.22e-05	0.000538	CcSEcCtD
Erlotinib—Pruritus—Gliclazide—type 2 diabetes mellitus	7.21e-05	0.000537	CcSEcCtD
Erlotinib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	7.17e-05	0.000534	CcSEcCtD
Erlotinib—Rash—Glyburide—type 2 diabetes mellitus	7.16e-05	0.000533	CcSEcCtD
Erlotinib—Dermatitis—Glyburide—type 2 diabetes mellitus	7.15e-05	0.000533	CcSEcCtD
Erlotinib—Syncope—Ramipril—type 2 diabetes mellitus	7.13e-05	0.000531	CcSEcCtD
Erlotinib—Headache—Glyburide—type 2 diabetes mellitus	7.11e-05	0.00053	CcSEcCtD
Erlotinib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	7.08e-05	0.000528	CcSEcCtD
Erlotinib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	6.99e-05	0.000521	CcSEcCtD
Erlotinib—Loss of consciousness—Ramipril—type 2 diabetes mellitus	6.99e-05	0.000521	CcSEcCtD
Erlotinib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	6.97e-05	0.000519	CcSEcCtD
Erlotinib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	6.97e-05	0.000519	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	6.95e-05	0.000517	CcSEcCtD
Erlotinib—Cough—Ramipril—type 2 diabetes mellitus	6.94e-05	0.000517	CcSEcCtD
Erlotinib—Fatigue—Irbesartan—type 2 diabetes mellitus	6.94e-05	0.000517	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	6.9e-05	0.000514	CcSEcCtD
Erlotinib—Pain—Irbesartan—type 2 diabetes mellitus	6.88e-05	0.000513	CcSEcCtD
Erlotinib—Constipation—Irbesartan—type 2 diabetes mellitus	6.88e-05	0.000513	CcSEcCtD
Erlotinib—Insomnia—Losartan—type 2 diabetes mellitus	6.85e-05	0.00051	CcSEcCtD
Erlotinib—Myalgia—Ramipril—type 2 diabetes mellitus	6.77e-05	0.000505	CcSEcCtD
Erlotinib—Arthralgia—Ramipril—type 2 diabetes mellitus	6.77e-05	0.000505	CcSEcCtD
Erlotinib—Chest pain—Ramipril—type 2 diabetes mellitus	6.77e-05	0.000505	CcSEcCtD
Erlotinib—Dyspnoea—Losartan—type 2 diabetes mellitus	6.75e-05	0.000503	CcSEcCtD
Erlotinib—Anxiety—Ramipril—type 2 diabetes mellitus	6.75e-05	0.000503	CcSEcCtD
Erlotinib—Nausea—Glyburide—type 2 diabetes mellitus	6.74e-05	0.000502	CcSEcCtD
Erlotinib—Abdominal pain—Metformin—type 2 diabetes mellitus	6.74e-05	0.000502	CcSEcCtD
Erlotinib—Dizziness—Gliclazide—type 2 diabetes mellitus	6.74e-05	0.000502	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	6.73e-05	0.000501	CcSEcCtD
Erlotinib—Asthenia—Valsartan—type 2 diabetes mellitus	6.72e-05	0.0005	CcSEcCtD
Erlotinib—Dyspepsia—Losartan—type 2 diabetes mellitus	6.67e-05	0.000497	CcSEcCtD
Erlotinib—Asthenia—Orlistat—type 2 diabetes mellitus	6.64e-05	0.000494	CcSEcCtD
Erlotinib—Pruritus—Valsartan—type 2 diabetes mellitus	6.62e-05	0.000493	CcSEcCtD
Erlotinib—Decreased appetite—Losartan—type 2 diabetes mellitus	6.58e-05	0.00049	CcSEcCtD
Erlotinib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	6.58e-05	0.00049	CcSEcCtD
Erlotinib—Pruritus—Orlistat—type 2 diabetes mellitus	6.55e-05	0.000488	CcSEcCtD
Erlotinib—Fatigue—Losartan—type 2 diabetes mellitus	6.53e-05	0.000486	CcSEcCtD
Erlotinib—Oedema—Ramipril—type 2 diabetes mellitus	6.49e-05	0.000484	CcSEcCtD
Erlotinib—Vomiting—Gliclazide—type 2 diabetes mellitus	6.48e-05	0.000483	CcSEcCtD
Erlotinib—Pain—Losartan—type 2 diabetes mellitus	6.48e-05	0.000482	CcSEcCtD
Erlotinib—Constipation—Losartan—type 2 diabetes mellitus	6.48e-05	0.000482	CcSEcCtD
Erlotinib—Rash—Gliclazide—type 2 diabetes mellitus	6.43e-05	0.000479	CcSEcCtD
Erlotinib—ABCB1—liver—type 2 diabetes mellitus	6.42e-05	0.00199	CbGeAlD
Erlotinib—Dermatitis—Gliclazide—type 2 diabetes mellitus	6.42e-05	0.000478	CcSEcCtD
Erlotinib—Diarrhoea—Valsartan—type 2 diabetes mellitus	6.41e-05	0.000477	CcSEcCtD
Erlotinib—Shock—Ramipril—type 2 diabetes mellitus	6.39e-05	0.000476	CcSEcCtD
Erlotinib—Headache—Gliclazide—type 2 diabetes mellitus	6.38e-05	0.000476	CcSEcCtD
Erlotinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	6.37e-05	0.000474	CcSEcCtD
Erlotinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	6.36e-05	0.000474	CcSEcCtD
Erlotinib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	6.36e-05	0.000474	CcSEcCtD
Erlotinib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	6.36e-05	0.000474	CcSEcCtD
Erlotinib—Diarrhoea—Orlistat—type 2 diabetes mellitus	6.33e-05	0.000472	CcSEcCtD
Erlotinib—Skin disorder—Ramipril—type 2 diabetes mellitus	6.31e-05	0.00047	CcSEcCtD
Erlotinib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	6.19e-05	0.000461	CcSEcCtD
Erlotinib—Dizziness—Valsartan—type 2 diabetes mellitus	6.19e-05	0.000461	CcSEcCtD
Erlotinib—Anorexia—Ramipril—type 2 diabetes mellitus	6.19e-05	0.000461	CcSEcCtD
Erlotinib—Dizziness—Orlistat—type 2 diabetes mellitus	6.12e-05	0.000456	CcSEcCtD
Erlotinib—Asthenia—Metformin—type 2 diabetes mellitus	6.12e-05	0.000456	CcSEcCtD
Erlotinib—Nausea—Gliclazide—type 2 diabetes mellitus	6.05e-05	0.000451	CcSEcCtD
Erlotinib—Pruritus—Metformin—type 2 diabetes mellitus	6.03e-05	0.000449	CcSEcCtD
Erlotinib—Body temperature increased—Losartan—type 2 diabetes mellitus	5.99e-05	0.000446	CcSEcCtD
Erlotinib—Abdominal pain—Losartan—type 2 diabetes mellitus	5.99e-05	0.000446	CcSEcCtD
Erlotinib—Vomiting—Valsartan—type 2 diabetes mellitus	5.95e-05	0.000443	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	5.92e-05	0.000441	CcSEcCtD
Erlotinib—Rash—Valsartan—type 2 diabetes mellitus	5.9e-05	0.00044	CcSEcCtD
Erlotinib—Dermatitis—Valsartan—type 2 diabetes mellitus	5.9e-05	0.000439	CcSEcCtD
Erlotinib—Vomiting—Orlistat—type 2 diabetes mellitus	5.88e-05	0.000438	CcSEcCtD
Erlotinib—Insomnia—Ramipril—type 2 diabetes mellitus	5.87e-05	0.000437	CcSEcCtD
Erlotinib—Headache—Valsartan—type 2 diabetes mellitus	5.87e-05	0.000437	CcSEcCtD
Erlotinib—Diarrhoea—Metformin—type 2 diabetes mellitus	5.83e-05	0.000435	CcSEcCtD
Erlotinib—Rash—Orlistat—type 2 diabetes mellitus	5.83e-05	0.000435	CcSEcCtD
Erlotinib—Dermatitis—Orlistat—type 2 diabetes mellitus	5.83e-05	0.000434	CcSEcCtD
Erlotinib—Headache—Orlistat—type 2 diabetes mellitus	5.8e-05	0.000432	CcSEcCtD
Erlotinib—Dyspnoea—Ramipril—type 2 diabetes mellitus	5.79e-05	0.000431	CcSEcCtD
Erlotinib—Asthenia—Irbesartan—type 2 diabetes mellitus	5.77e-05	0.00043	CcSEcCtD
Erlotinib—Dyspepsia—Ramipril—type 2 diabetes mellitus	5.72e-05	0.000426	CcSEcCtD
Erlotinib—Pruritus—Irbesartan—type 2 diabetes mellitus	5.69e-05	0.000424	CcSEcCtD
Erlotinib—Decreased appetite—Ramipril—type 2 diabetes mellitus	5.64e-05	0.00042	CcSEcCtD
Erlotinib—Dizziness—Metformin—type 2 diabetes mellitus	5.64e-05	0.00042	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	5.61e-05	0.000418	CcSEcCtD
Erlotinib—Fatigue—Ramipril—type 2 diabetes mellitus	5.6e-05	0.000417	CcSEcCtD
Erlotinib—Nausea—Valsartan—type 2 diabetes mellitus	5.56e-05	0.000414	CcSEcCtD
Erlotinib—Constipation—Ramipril—type 2 diabetes mellitus	5.55e-05	0.000414	CcSEcCtD
Erlotinib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	5.51e-05	0.00041	CcSEcCtD
Erlotinib—Nausea—Orlistat—type 2 diabetes mellitus	5.5e-05	0.000409	CcSEcCtD
Erlotinib—Asthenia—Losartan—type 2 diabetes mellitus	5.43e-05	0.000405	CcSEcCtD
Erlotinib—Vomiting—Metformin—type 2 diabetes mellitus	5.42e-05	0.000404	CcSEcCtD
Erlotinib—Rash—Metformin—type 2 diabetes mellitus	5.38e-05	0.0004	CcSEcCtD
Erlotinib—Dermatitis—Metformin—type 2 diabetes mellitus	5.37e-05	0.0004	CcSEcCtD
Erlotinib—Pruritus—Losartan—type 2 diabetes mellitus	5.36e-05	0.000399	CcSEcCtD
Erlotinib—Headache—Metformin—type 2 diabetes mellitus	5.34e-05	0.000398	CcSEcCtD
Erlotinib—Dizziness—Irbesartan—type 2 diabetes mellitus	5.32e-05	0.000396	CcSEcCtD
Erlotinib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	5.31e-05	0.000396	CcSEcCtD
Erlotinib—Diarrhoea—Losartan—type 2 diabetes mellitus	5.18e-05	0.000386	CcSEcCtD
Erlotinib—Abdominal pain—Ramipril—type 2 diabetes mellitus	5.13e-05	0.000382	CcSEcCtD
Erlotinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	5.13e-05	0.000382	CcSEcCtD
Erlotinib—Vomiting—Irbesartan—type 2 diabetes mellitus	5.12e-05	0.000381	CcSEcCtD
Erlotinib—Rash—Irbesartan—type 2 diabetes mellitus	5.07e-05	0.000378	CcSEcCtD
Erlotinib—Dermatitis—Irbesartan—type 2 diabetes mellitus	5.07e-05	0.000378	CcSEcCtD
Erlotinib—Nausea—Metformin—type 2 diabetes mellitus	5.06e-05	0.000377	CcSEcCtD
Erlotinib—Headache—Irbesartan—type 2 diabetes mellitus	5.04e-05	0.000375	CcSEcCtD
Erlotinib—Dizziness—Losartan—type 2 diabetes mellitus	5.01e-05	0.000373	CcSEcCtD
Erlotinib—Vomiting—Losartan—type 2 diabetes mellitus	4.81e-05	0.000359	CcSEcCtD
Erlotinib—Nausea—Irbesartan—type 2 diabetes mellitus	4.78e-05	0.000356	CcSEcCtD
Erlotinib—Rash—Losartan—type 2 diabetes mellitus	4.77e-05	0.000356	CcSEcCtD
Erlotinib—Dermatitis—Losartan—type 2 diabetes mellitus	4.77e-05	0.000355	CcSEcCtD
Erlotinib—Headache—Losartan—type 2 diabetes mellitus	4.74e-05	0.000353	CcSEcCtD
Erlotinib—Asthenia—Ramipril—type 2 diabetes mellitus	4.66e-05	0.000347	CcSEcCtD
Erlotinib—Pruritus—Ramipril—type 2 diabetes mellitus	4.59e-05	0.000342	CcSEcCtD
Erlotinib—Nausea—Losartan—type 2 diabetes mellitus	4.5e-05	0.000335	CcSEcCtD
Erlotinib—Diarrhoea—Ramipril—type 2 diabetes mellitus	4.44e-05	0.000331	CcSEcCtD
Erlotinib—Dizziness—Ramipril—type 2 diabetes mellitus	4.29e-05	0.00032	CcSEcCtD
Erlotinib—Vomiting—Ramipril—type 2 diabetes mellitus	4.13e-05	0.000308	CcSEcCtD
Erlotinib—Rash—Ramipril—type 2 diabetes mellitus	4.09e-05	0.000305	CcSEcCtD
Erlotinib—Dermatitis—Ramipril—type 2 diabetes mellitus	4.09e-05	0.000305	CcSEcCtD
Erlotinib—Headache—Ramipril—type 2 diabetes mellitus	4.07e-05	0.000303	CcSEcCtD
Erlotinib—Nausea—Ramipril—type 2 diabetes mellitus	3.86e-05	0.000287	CcSEcCtD
Erlotinib—CYP2C8—Metabolism—CAT—type 2 diabetes mellitus	1.85e-06	1.89e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAT—type 2 diabetes mellitus	1.84e-06	1.88e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ADCY5—type 2 diabetes mellitus	1.83e-06	1.87e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	1.82e-06	1.86e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GPX1—type 2 diabetes mellitus	1.82e-06	1.86e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—type 2 diabetes mellitus	1.82e-06	1.86e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.82e-06	1.86e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	1.82e-06	1.86e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—type 2 diabetes mellitus	1.81e-06	1.85e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOB—type 2 diabetes mellitus	1.8e-06	1.83e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	1.79e-06	1.83e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	1.79e-06	1.83e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOB—type 2 diabetes mellitus	1.79e-06	1.82e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—type 2 diabetes mellitus	1.78e-06	1.82e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SRC—type 2 diabetes mellitus	1.78e-06	1.81e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CD36—type 2 diabetes mellitus	1.78e-06	1.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—INS—type 2 diabetes mellitus	1.77e-06	1.81e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.77e-06	1.81e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	1.76e-06	1.79e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.75e-06	1.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	1.75e-06	1.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	1.75e-06	1.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	1.75e-06	1.79e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	1.75e-06	1.78e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—type 2 diabetes mellitus	1.75e-06	1.78e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	1.75e-06	1.78e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—type 2 diabetes mellitus	1.74e-06	1.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.74e-06	1.78e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	1.74e-06	1.77e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	1.74e-06	1.77e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.74e-06	1.77e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	1.72e-06	1.75e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	1.71e-06	1.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.71e-06	1.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.71e-06	1.75e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	1.71e-06	1.74e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—LPL—type 2 diabetes mellitus	1.7e-06	1.74e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	1.69e-06	1.73e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.69e-06	1.73e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—type 2 diabetes mellitus	1.68e-06	1.72e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.68e-06	1.72e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	1.68e-06	1.71e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	1.67e-06	1.71e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	1.67e-06	1.7e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	1.67e-06	1.7e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	1.67e-06	1.7e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GPX1—type 2 diabetes mellitus	1.66e-06	1.7e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	1.66e-06	1.69e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARA—type 2 diabetes mellitus	1.65e-06	1.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—SRC—type 2 diabetes mellitus	1.64e-06	1.67e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.64e-06	1.67e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.64e-06	1.67e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	1.64e-06	1.67e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.63e-06	1.67e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.63e-06	1.67e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	1.63e-06	1.66e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.63e-06	1.66e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CD36—type 2 diabetes mellitus	1.62e-06	1.65e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.61e-06	1.64e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	1.61e-06	1.64e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	1.6e-06	1.64e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AGT—type 2 diabetes mellitus	1.6e-06	1.63e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	1.6e-06	1.63e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	1.59e-06	1.62e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	1.59e-06	1.62e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.58e-06	1.61e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CALM1—type 2 diabetes mellitus	1.57e-06	1.6e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOE—type 2 diabetes mellitus	1.57e-06	1.6e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.56e-06	1.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.55e-06	1.59e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.55e-06	1.59e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOA1—type 2 diabetes mellitus	1.55e-06	1.58e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.55e-06	1.58e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.55e-06	1.58e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.55e-06	1.58e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.55e-06	1.58e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	1.55e-06	1.58e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	1.54e-06	1.57e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.54e-06	1.57e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.54e-06	1.57e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	1.54e-06	1.57e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.52e-06	1.55e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	1.52e-06	1.55e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	1.52e-06	1.55e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.52e-06	1.55e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.52e-06	1.55e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	1.51e-06	1.54e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.51e-06	1.54e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.51e-06	1.54e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.51e-06	1.54e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARA—type 2 diabetes mellitus	1.51e-06	1.54e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.5e-06	1.53e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.49e-06	1.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.47e-06	1.5e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.47e-06	1.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—type 2 diabetes mellitus	1.47e-06	1.5e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	1.47e-06	1.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RELA—type 2 diabetes mellitus	1.46e-06	1.49e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.46e-06	1.49e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AGT—type 2 diabetes mellitus	1.46e-06	1.49e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.46e-06	1.49e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.46e-06	1.48e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	1.45e-06	1.47e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.44e-06	1.47e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	1.44e-06	1.47e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	1.44e-06	1.47e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CALM1—type 2 diabetes mellitus	1.43e-06	1.46e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.43e-06	1.46e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOE—type 2 diabetes mellitus	1.43e-06	1.46e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	1.42e-06	1.45e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.42e-06	1.45e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	1.42e-06	1.45e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOA1—type 2 diabetes mellitus	1.41e-06	1.44e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.41e-06	1.44e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.4e-06	1.43e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—type 2 diabetes mellitus	1.4e-06	1.43e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.38e-06	1.41e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.37e-06	1.4e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—type 2 diabetes mellitus	1.37e-06	1.39e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.35e-06	1.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.35e-06	1.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.35e-06	1.38e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.35e-06	1.37e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—INS—type 2 diabetes mellitus	1.34e-06	1.37e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.34e-06	1.36e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.33e-06	1.36e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.33e-06	1.35e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.32e-06	1.35e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.32e-06	1.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.32e-06	1.35e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.32e-06	1.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.31e-06	1.34e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	1.31e-06	1.34e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.31e-06	1.34e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	1.3e-06	1.33e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	1.3e-06	1.33e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	1.29e-06	1.32e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.29e-06	1.31e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	1.29e-06	1.31e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.28e-06	1.3e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.27e-06	1.29e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.26e-06	1.28e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.25e-06	1.28e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	1.25e-06	1.28e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	1.25e-06	1.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.25e-06	1.27e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—type 2 diabetes mellitus	1.24e-06	1.27e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.24e-06	1.27e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	1.24e-06	1.27e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	1.24e-06	1.27e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.24e-06	1.26e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.24e-06	1.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.23e-06	1.26e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	1.23e-06	1.25e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—type 2 diabetes mellitus	1.23e-06	1.25e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.22e-06	1.25e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.22e-06	1.25e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—INS—type 2 diabetes mellitus	1.22e-06	1.25e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	1.21e-06	1.24e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	1.21e-06	1.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.21e-06	1.23e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.2e-06	1.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—type 2 diabetes mellitus	1.2e-06	1.22e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	1.19e-06	1.22e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.18e-06	1.21e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.18e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.17e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NOS3—type 2 diabetes mellitus	1.17e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.17e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.17e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	1.17e-06	1.19e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.17e-06	1.19e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	1.16e-06	1.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SRC—type 2 diabetes mellitus	1.15e-06	1.17e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	1.14e-06	1.16e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	1.13e-06	1.16e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	1.13e-06	1.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.12e-06	1.14e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	1.12e-06	1.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—type 2 diabetes mellitus	1.11e-06	1.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—type 2 diabetes mellitus	1.1e-06	1.13e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.09e-06	1.11e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	1.08e-06	1.1e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	1.08e-06	1.1e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—type 2 diabetes mellitus	1.07e-06	1.1e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	1.07e-06	1.1e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	1.07e-06	1.09e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NOS3—type 2 diabetes mellitus	1.07e-06	1.09e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.07e-06	1.09e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	1.05e-06	1.07e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.03e-06	1.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.03e-06	1.05e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	1.02e-06	1.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—type 2 diabetes mellitus	1.02e-06	1.04e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.01e-06	1.03e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.01e-06	1.03e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.01e-06	1.03e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.01e-06	1.03e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	1e-06	1.02e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	1e-06	1.02e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	9.93e-07	1.01e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	9.88e-07	1.01e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	9.85e-07	1e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	9.81e-07	1e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	9.79e-07	9.99e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	9.64e-07	9.83e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—type 2 diabetes mellitus	9.4e-07	9.59e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	9.38e-07	9.57e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	9.38e-07	9.57e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	9.38e-07	9.56e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	9.24e-07	9.43e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	9.2e-07	9.39e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	9.01e-07	9.19e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	8.98e-07	9.16e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	8.84e-07	9.02e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	8.84e-07	9.02e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—type 2 diabetes mellitus	8.77e-07	8.94e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	8.75e-07	8.92e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	8.71e-07	8.88e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	8.64e-07	8.81e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	8.58e-07	8.75e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	8.54e-07	8.71e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	8.29e-07	8.45e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	8.13e-07	8.29e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	8.09e-07	8.25e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	7.98e-07	8.14e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	7.87e-07	8.03e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	7.83e-07	7.99e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—type 2 diabetes mellitus	7.74e-07	7.9e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	7.74e-07	7.9e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	7.71e-07	7.87e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	7.63e-07	7.78e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	7.49e-07	7.64e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	7.49e-07	7.64e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.14e-07	7.29e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	6.85e-07	6.99e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	6.72e-07	6.85e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	6.59e-07	6.72e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	6.04e-07	6.16e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	5.78e-07	5.9e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	5.78e-07	5.9e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	5.71e-07	5.83e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—type 2 diabetes mellitus	5.4e-07	5.51e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	5.29e-07	5.39e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	4.95e-07	5.05e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—type 2 diabetes mellitus	4.92e-07	5.02e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	4.31e-07	4.4e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	4.06e-07	4.14e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	3.44e-07	3.51e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.66e-07	2.71e-06	CbGpPWpGaD
